BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Contract Services

I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

Encouraging efficacy signals were observed in a non-small cell lung cancer (NSCLC) patient cohort - Results indicate CD73 expression corr...

May 27, 2022 | News

Hanmi Fine Chemical Launches 'high-tech CDMO' Business

10 billion KRW invested in Hanmi Fine Chemical facility expansion Hanmi Fine Chemical (hereinafter Hanmi FC) a subsidiary of Hanmi Pharmaceutic...

May 23, 2022 | News

Vetter Achieves a Three-Peat in Winning the Best Managed Companies Award

Company efforts balance strategic growth and sustainability A successful record of meeting increasing market dynamics Ongoing commitment to fulfilling ...

May 19, 2022 | News

Novotech Sponsors Pre-ASCO China Summit: Go/No Go Decisions Based on Early Phase Oncology Trials

The Summit will feature insights from leading Novotech experts tapping decades of oncology clinical experience in the APAC region. They include:- Dr. Raman...

May 12, 2022 | News

Bora Pharmaceuticals acquires Eden Biologics CDMO Assets

Taiwan-based premier international contract development and manufacturing organization (CDMO) Bora Pharmaceuticals recently announced the establishment of ...

May 11, 2022 | News

Novotech Acquires US CRO NCGS, Expands Global Expertise

Novotech CEO Dr. John Moller said "We are very pleased to acquire such an impressive company with a strong history of quality and delivery in the United St...

May 05, 2022 | News

Inmagene Receives FDA's IND Clearance for OX40 Antagonist

IMG-007 is highly potent at blocking the binding of OX40 to OX40L, thereby reducing OX40L-dependent downstream signaling and cytokine release by T cells. I...

May 02, 2022 | News

Lessons Learned from COVID-19 Vaccine Trials

IQVIA Institute releases report on Lessons Learned from COVID-19 Vaccine Trials Solutions for you to dri...

April 28, 2022 | News

WuXi Biologics' 2021 ESG Report Reveals Company's Strong Commitment to Overall Sustainability

One example of WuXi Biologics' contribution to society is its rapid, robust pandemic response -- enabling nearly 30 Investigational New Drug Applications (...

April 28, 2022 | News

Samsung Biologics completes full acquisition of Samsung Bioepis

Samsung Biologics (KRX: 207940.KS) announced today that it has completed the purchase of Biogen's stake in the Samsung Bioepis joint venture for USD $...

April 21, 2022 | News

ImmVira enters clinical development in combination therapy of MVR-T3011 IT and MEK inhibitor in the U.S

MVR-T3011, ImmVira's proprietary 3-in-1oncolytic herpes simplex virus ("oHSV"), is a novel genetically engineered oHSV which aims to achieve the ...

April 20, 2022 | News

WuXi Biologics Receives Bioprocessing Excellence Award from IMAPAC

This marks the second consecutive year that WuXi Bio has received this award from IMAPAC, a leading consulting firm in biopharmaceutical industry. S...

April 18, 2022 | News

Merck Advances BioProcessing Capabilities with Acquisition of MAST® Platform from Lonza

Merck to become first company to offer a fully integrated ecosystem for advanced process technologies Brings biopharmaceutical industry closer to digita...

April 14, 2022 | News

CDMO's Shifting Focus to Meet Future Demand

Transformational forces are influencing the global contract development and manufacturing organization (CDMO) market's growth. Disruptive, innovative busin...

April 08, 2022 | News

Stay Connected